Feasibility investigation of allogeneic endometrial regenerative cells.
Endometrial Regenerative Cells (ERC) are a population of mesenchymal-like stem cells having pluripotent differentiation activity and ability to induce neoangiogenesis. In vitro and animal studies suggest ERC are immune privileged and in certain situations actively suppress ongoing immune responses. In this paper we describe the production of clinical grade ERC and initial safety experiences in 4 patients with multiple sclerosis treated intravenously and intrathecally. The case with the longest follow up, of more than one year, revealed no immunological reactions or treatment associated adverse effects. These preliminary data suggest feasibility of clinical ERC administration and support further studies with this novel stem cell type.
Zhong
Zhaohui
Z
Medistem Inc, San Diego, USA. jzhonguro@gmail.com
Patel
Amit N
AN
Ichim
Thomas E
TE
Riordan
Neil H
NH
Wang
Hao
H
Min
Wei-Ping
WP
Woods
Erik J
EJ
Reid
Michael
M
Mansilla
Eduardo
E
Marin
Gustavo H
GH
Drago
Hugo
H
Murphy
Michael P
MP
Minev
Boris
B
D000328:Adult; D004717:Endometrium / Q000166:cytology* / Q000473:pathology*; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000473:pathology / Q000601:surgery*; D039904:Pluripotent Stem Cells / Q000166:cytology / Q000637:transplantation*; D012038:Regeneration; D014184:Transplantation, Homologous